csirt@kutim:~/threat-intel/cve/CVE-2026-77802

Katalog CVE

CVSS 6.3 · Medium EPSS 0,09%

Kerentanan Inconsistent Interpretation of HTTP Requests ('HTTP Request/Response Smuggling'). Skor CVSS 3.1 6.3 (Medium) menurut progress.com.

Deskripsi (NVD)

In Progress® Telerik® Fiddler® Classic for Windows, versions prior to v6.0.20262.10021, HTTP request smuggling is possible in the proxy request forwarding component. Requests containing multiple Content-Length headers with conflicting values are forwarded verbatim to the origin server, while Fiddler frames the request body using only the first Content-Length value. A local threat actor with low privileges who is able to send requests through the same Fiddler proxy instance as another user can exploit this desynchronization against a non-RFC-9110-compliant origin server that keeps the connection alive to smuggle an additional request. Because Fiddler returns the server connection to its pipe pool after reading only the first response, the unread smuggled response remains buffered on the socket and is served to the next session that reuses that connection, allowing the attacker to poison responses delivered to other users and to obtain responses intended for them.

Rincian

Terbit di NVD
5 Oktober 2026
Terakhir diubah
6 Oktober 2026
Status NVD
Awaiting Analysis
CVSS 3.1
6.3 (Medium), sumber progress.com
CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-444: Inconsistent Interpretation of HTTP Requests ('HTTP Request/Response Smuggling')
EPSS (30 hari)
0,09% peluang dieksploitasi; lebih tinggi dari 0,5% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 7 Okt 2026, 06:33 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.